Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Applied Therapeutics, Inc. Director's Dealing 2022

Jan 12, 2022

34263_dirs_2022-01-11_924c392e-e19e-4ff7-b2d5-b13b34228dba.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Applied Therapeutics Inc. (APLT)
CIK: 0001697532
Period of Report: 2022-01-07

Reporting Person: Shendelman Shoshana (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-01-07 Common Stock A 120900 $0.00 Acquired 606086 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-07 Employee Stock Option (Right to Buy) $4.17 A 80600 Acquired 2032-01-07 Common Stock (80600) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1750000 Indirect
Common Stock 1492094 Indirect
Common Stock 709720 Indirect
Common Stock 290280 Indirect
Common Stock 88397 Indirect

Footnotes

F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on January 7, 2023, and one-twelfth (1/12th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each quarter thereafter, subject to the Reporting Person continuing to provide services through each such date.

F2: Through a grantor retained annuity trust.

F3: Through a family trust controlled by the reporting person's spouse.

F4: Through the reporting person's spouse.

F5: Through a family trust controlled by the reporting person.

F6: Through Clearpoint Strategy Group LLC of which the reporting person is the sole owner.

F7: Consists of compensatory Options granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-fourth (1/4th) of the shares subject to the compensatory Option shall vest on January 7, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Option shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.